Guided Anti-P2Y12 Therapy in Patients Undergoing Percutaneous Coronary Intervention
Thrombosis and Haemostasis · 01.06.2024 · 124 (06) · 595-597
DOI: 10.1055/a-2216-5263 ↗Kurz gefasst
Leserbrief in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.06.2024. Verfasst von Marco Cattaneo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Divisione di Medicina Generale II, ASST Santi Paolo e Carlo, Dipartimento di Scienze della Salute, Università degli Studi di Milano, Milan, Italy. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Purinergic P2Y Receptor Antagonists, Postoperative Complications, Thrombosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Divisione di Medicina Generale II, ASST Santi Paolo e Carlo, Dipartimento di Scienze della Salute, Università degli Studi di Milano, Milan, Italy.
- Fondazione Arianna Anticoagulazione, Bologna, Italy.
- Research Center on Thromboembolic Disorders and Antithrombotic Therapies, ASST Lariana, University of Insubria, Como, Italy.
ORCID-Profile: Marco Cattaneo, Alessandro Squizzato, Gian Marco Podda
Zitieren
APA
Cattaneo, M., Squizzato, A., Birocchi, S., & Podda, G. M. (2024). Guided Anti-P2Y12 Therapy in Patients Undergoing Percutaneous Coronary Intervention. Thrombosis and Haemostasis, 124(06), 595-597. https://doi.org/10.1055/a-2216-5263
Vancouver
Cattaneo M, Squizzato A, Birocchi S, Podda GM. Guided Anti-P2Y12 Therapy in Patients Undergoing Percutaneous Coronary Intervention. Thrombosis and Haemostasis. 2024;124(06):595-597. doi:10.1055/a-2216-5263
BibTeX
@article{Cattaneo2024,
author = {Cattaneo, Marco and Squizzato, Alessandro and Birocchi, Simone and Podda, Gian Marco},
title = {Guided Anti-P2Y12 Therapy in Patients Undergoing Percutaneous Coronary Intervention},
journal = {Thrombosis and Haemostasis},
year = {2024},
volume = {124},
number = {06},
pages = {595--597},
doi = {10.1055/a-2216-5263}
}
EUVIMED